Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
levetiracetam, Quantity: 100 mg/mL
Arrotex Pharmaceuticals Pty Ltd
Levetiracetam
Injection, intravenous infusion
Excipient Ingredients: sodium acetate trihydrate; sodium chloride; glacial acetic acid; water for injections
Intravenous Infusion
10 x 5mL vials
(S4) Prescription Only Medicine
Levetiracetam concentrate solution for IV infusion after dilution is an alternative for patients when oral administration is temporarily not feasible. Use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation; monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy (JME); and, add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (IGE).
Visual Identification: A clear, colourless, sterile solution.; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Licence status A
2015-03-12